Human breast cancer cell line that overexpresses the Her2 (Neu/ErbB-2) gene product. These cells display an epithelial morphology in tissue culture.
| Inventor | Institute |
|---|---|
| Lloyd J. Old, Germain Trempe | Memorial Sloan-Kettering Cancer Center (MSK) |
| SKU: | 161911 |
|---|---|
| Product description: | SK-BR-3 is a human breast cancer cell line that overexpresses the Her2 (Neu/ErbB-2) gene product. These cells display an epithelial morphology in tissue culture and are capable of forming poorly differentiated tumours in immunocompromised mice. The SK-BR-3 cells and products derived from it are used often as positive controls in assays for Her2. In addition, the cell line is also a useful preclinical model to screen for therapeutic agents targeting Her2 and to delineate mechanisms of resistance to Her2-targeted therapies. |
| Gender: | Male |
| Cat. #: | 161911 |
|---|---|
| Tool sub type: | Continuous |
| Cancer types: | Breast cancer |
| Organism: | Human |
| Tissue: | Breast; Mammary gland |
| Gender: | Male |
| Morphology: | Epithelial; Ultrastructural features include microvilli and desmosomes, glycogen granules, large lysosomes, bundles of cytoplasmic fibrils. |
| Growth properties: | Adherent |
| Primary citation: | Fogh J et al. 1977. Journal of the National Cancer Institute. 59: 221-226.PMID: 327080. |
| Storage conditions: | Vapor phase of liquid nitrogen. Storage at -70° C will result in loss of viability. |
|---|---|
| Shipping conditions: | Dry Ice |
| Growth medium: | McCoy’s 5a Medium Modified supplemented with 10% FBS |
| Temperature: | 37° C |
| Atmosphere: | 95% Air, 5% CO2 |
| Storage medium: | Complete growth medium, 95%; DMSO, 5% |
| Biosafety level: | 1 |
| References: |
Fogh J et al. 1977. Journal of the National Cancer Institute. 59: 221-226.PMID: 327080. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.